UK Markets open in 27 mins

FTSE 100: AstraZeneca breast cancer drug gets EU backing

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·2-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
SHANGHAI, CHINA - JULY 7, 2021 - The Astrazeneca logo is pictured at the World Artificial Intelligence Conference 2021 in Shanghai, China, July 7, 2021. On January 29, 2022, Astrazeneca notified the outside world that employees were suspected of falsifying genetic test results of cancer patients to defraud medicare funds. (Photo credit should read Costfoto/Future Publishing via Getty Images)
AstraZeneca shares fell after the announcement. Photo: Costfoto/Future Publishing via Getty

AstraZeneca (AZN.L) said on Monday its Enhertu and Lynparza drugs have been recommended for approval in the European Union for patients with breast cancer.

According to the Anglo-Swedish drugs giant its Lynparza treatment has been recommended for marketing in the EU by the Committee for Medicinal Products for Human Use for early breast cancer treatment, after positive phase-three results.

It said the drug, a HER2-negative high-risk early breast cancer treatment, had demonstrated "a statistically significant and clinically meaningful" improvement in invasive disease-free survival.

In the trial, Lynparza was shown to reduce the risk of invasive breast cancer recurrences, new cancers, or death by 42% compared to placebo.

It also showed an improvement in overall survival by lowering the risk of death by 32% versus placebo.

Shares in the FTSE 100 (^FTSE) firm fell 0.4% in afternoon trade on Monday in London.

Susan Galbraith, AstraZeneca's executive vice president of oncology R&D, said: "If approved, Lynparza will become a new targeted treatment option for patients with germline BRCA-mutated HER2-negative early breast cancer in Europe.

"By treating patients with curative-intent as early as possible in their disease, we hope to avoid life-threatening recurrence and give people more time with their loved ones."

Read more: Wise: City watchdog investigates fintech CEO after he 'failed to pay taxes'

Separately, its Enhertu drug, a monotherapy for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer, had also received recommendation for use in the US following the Destiny-Breast03 trial.

If a tumour is considered to be "resectable" it means that it is able to be removed with surgery.

The drug has been jointly developed and commercialised by AstraZeneca and Daiichi Sankyo Co (4568.T).

Results of the trial showed AstraZeneca and Daiichi Sankyo's candidate reduced the risk of disease progression or death by 72% compared with the trastuzumab emtansine drug.

Watch: What are SPACs?

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting